Cinquegrani G - Search Results

1

Empagliflozin does not reverse lipotoxicity-induced impairment in human myeloid angiogenic cell bioenergetics.

Cinquegrani G, Spigoni V, Fantuzzi F, Bonadonna RC, Dei Cas A. Cinquegrani G, et al. Cardiovasc Diabetol. 2022 Feb 17;21(1):27. doi: 10.1186/s12933-022-01461-4. Cardiovasc Diabetol. 2022. PMID: 35177077 Free PMC article.

2

SARS-CoV-2 Spike protein is not pro-inflammatory in human primary macrophages: endotoxin contamination and lack of protein glycosylation as possible confounders.

Cinquegrani G, Spigoni V, Iannozzi NT, Parello V, Bonadonna RC, Dei Cas A. Cinquegrani G, et al. Cell Biol Toxicol. 2022 Aug;38(4):667-678. doi: 10.1007/s10565-021-09693-y. Epub 2022 Jan 11. Cell Biol Toxicol. 2022. PMID: 35015170 Free PMC article.

3

Chronic consumption of a bergamot-based beverage does not affect glucose, lipid and inflammatory biomarkers of cardiometabolic risk in healthy subjects: a randomised controlled intervention study.

Maggiolo G, Aldigeri R, Savini C, Mengani M, Maggi M, Frigeri G, Spigoni V, Cinquegrani G, Fantuzzi F, Di Donna L, Tosi N, Bergamo F, Bresciani L, Rosi A, Mena P, Scazzina F, Del Rio D, Bonadonna RC, Dei Cas A. Maggiolo G, et al. Among authors: cinquegrani g. Food Funct. 2024 May 20. doi: 10.1039/d4fo00877d. Online ahead of print. Food Funct. 2024. PMID: 38767145

4

Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial.

Dei Cas A, Micheli MM, Aldigeri R, Gardini S, Ferrari-Pellegrini F, Perini M, Messa G, Antonini M, Spigoni V, Cinquegrani G, Vazzana A, Moretti V, Caffarra P, Bonadonna RC. Dei Cas A, et al. Among authors: cinquegrani g. J Endocrinol Invest. 2024 Apr 2. doi: 10.1007/s40618-024-02320-7. Online ahead of print. J Endocrinol Invest. 2024. PMID: 38565814

5

Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders.

Spigoni V, Cinquegrani G, Iannozzi NT, Frigeri G, Maggiolo G, Maggi M, Parello V, Dei Cas A. Spigoni V, et al. Among authors: cinquegrani g. Front Endocrinol (Lausanne). 2022 Oct 20;13:972890. doi: 10.3389/fendo.2022.972890. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36339405 Free PMC article. Review.

6

PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.

Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: cinquegrani g. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6 results

Search Page